Several elements combine to make GlaxoSmithKline a winning investment proposition for both individuals and institutions – the company’s market strength, its history of providing innovative products to meet patient needs, its new product pipeline, not to mention its unrivalled R&D capability and the knowledge and skills of its people.

GlaxoSmithKline currently has a market value of approximately £110 billion and represents around nine per cent of the FTSE100 index. In terms of sales, it is the largest pharmaceutical company in Europe and one of the largest in the world.